Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma
Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti...
Gespeichert in:
Veröffentlicht in: | Molecular pharmaceutics 2023-08, Vol.20 (8), p.4319-4330 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4330 |
---|---|
container_issue | 8 |
container_start_page | 4319 |
container_title | Molecular pharmaceutics |
container_volume | 20 |
creator | Dorst, Daphne N. Smeets, Esther M. M. Klein, Christian Frielink, Cathelijne Geijs, Daan Trajkovic-Arsic, Marija Cheung, Phyllis F. Y. Stommel, Martijn W. J. Gotthardt, Martin Siveke, Jens T. Aarntzen, Erik H. J. G. van Lith, Sanne A. M. |
description | Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of 111In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (CKP). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In CKP mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC. |
doi_str_mv | 10.1021/acs.molpharmaceut.3c00453 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10410663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2841401078</sourcerecordid><originalsourceid>FETCH-LOGICAL-a470t-980bcdfb38fc06d232c58ba3a2b3931aba62362ad056a849e038e0490bc34ef73</originalsourceid><addsrcrecordid>eNqNkctuEzEUhq0KRC_wCsjs2EzwbSaeFYpCW5BakUVYW2c8ZxpXM3awPZXyGjxxJ0pI6Y6VLfn_v3Pkj5BPnM04E_wL2DQbQr_dQBzA4phn0jKmSnlGLnipZKFlLd6c7lqdk8uUHhkTqhTyHTmXc6VLrasL8ufGNTE0PaRMFza7J8gueLqKIaPzxRriA2Zs6WoTcmh3HgZn6XqDEbY7Gjq6BG8xFouUgnWwT74AE3We3o_ReaT3ocU-0S5EupoqEac5ln4bbYaeLlr0wUK0zocB3pO3HfQJPxzPK_Lr5nq9_F7c_bz9sVzcFaDmLBe1Zo1tu0bqzrKqFVLYUjcgQTSylhwaqISsBLSsrECrGpnUyFQ9taTCbi6vyNcDdzs2A7YWfY7Qm210A8SdCeDM6xfvNuYhPBnOFGdVJSfC5yMhht8jpmwGlyz2PXgMYzJCK64YZ3M9RetD1MaQUsTuNIczs5dqJqnmlVRzlDp1P_676Kn51-IUKA-BPeMxjNFP__Yf4GfgNrrN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2841401078</pqid></control><display><type>article</type><title>Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma</title><source>MEDLINE</source><source>ACS Publications</source><creator>Dorst, Daphne N. ; Smeets, Esther M. M. ; Klein, Christian ; Frielink, Cathelijne ; Geijs, Daan ; Trajkovic-Arsic, Marija ; Cheung, Phyllis F. Y. ; Stommel, Martijn W. J. ; Gotthardt, Martin ; Siveke, Jens T. ; Aarntzen, Erik H. J. G. ; van Lith, Sanne A. M.</creator><creatorcontrib>Dorst, Daphne N. ; Smeets, Esther M. M. ; Klein, Christian ; Frielink, Cathelijne ; Geijs, Daan ; Trajkovic-Arsic, Marija ; Cheung, Phyllis F. Y. ; Stommel, Martijn W. J. ; Gotthardt, Martin ; Siveke, Jens T. ; Aarntzen, Erik H. J. G. ; van Lith, Sanne A. M.</creatorcontrib><description>Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of 111In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (CKP). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In CKP mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.3c00453</identifier><identifier>PMID: 37485886</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Animals ; Antibodies - metabolism ; Cancer-Associated Fibroblasts ; Carcinoma, Pancreatic Ductal - pathology ; Caspase 3 - metabolism ; Cell Line, Tumor ; Disease Models, Animal ; Fibroblasts - metabolism ; Mice ; Pancreatic Neoplasms ; Pancreatic Neoplasms - metabolism ; Photochemotherapy ; Serine Endopeptidases - metabolism ; Tissue Distribution</subject><ispartof>Molecular pharmaceutics, 2023-08, Vol.20 (8), p.4319-4330</ispartof><rights>2023 The Authors. Published by American Chemical Society</rights><rights>2023 The Authors. Published by American Chemical Society 2023 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a470t-980bcdfb38fc06d232c58ba3a2b3931aba62362ad056a849e038e0490bc34ef73</citedby><cites>FETCH-LOGICAL-a470t-980bcdfb38fc06d232c58ba3a2b3931aba62362ad056a849e038e0490bc34ef73</cites><orcidid>0000-0001-8584-2546</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c00453$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00453$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,780,784,885,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37485886$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dorst, Daphne N.</creatorcontrib><creatorcontrib>Smeets, Esther M. M.</creatorcontrib><creatorcontrib>Klein, Christian</creatorcontrib><creatorcontrib>Frielink, Cathelijne</creatorcontrib><creatorcontrib>Geijs, Daan</creatorcontrib><creatorcontrib>Trajkovic-Arsic, Marija</creatorcontrib><creatorcontrib>Cheung, Phyllis F. Y.</creatorcontrib><creatorcontrib>Stommel, Martijn W. J.</creatorcontrib><creatorcontrib>Gotthardt, Martin</creatorcontrib><creatorcontrib>Siveke, Jens T.</creatorcontrib><creatorcontrib>Aarntzen, Erik H. J. G.</creatorcontrib><creatorcontrib>van Lith, Sanne A. M.</creatorcontrib><title>Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of 111In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (CKP). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In CKP mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC.</description><subject>Animals</subject><subject>Antibodies - metabolism</subject><subject>Cancer-Associated Fibroblasts</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Caspase 3 - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Disease Models, Animal</subject><subject>Fibroblasts - metabolism</subject><subject>Mice</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Photochemotherapy</subject><subject>Serine Endopeptidases - metabolism</subject><subject>Tissue Distribution</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctuEzEUhq0KRC_wCsjs2EzwbSaeFYpCW5BakUVYW2c8ZxpXM3awPZXyGjxxJ0pI6Y6VLfn_v3Pkj5BPnM04E_wL2DQbQr_dQBzA4phn0jKmSnlGLnipZKFlLd6c7lqdk8uUHhkTqhTyHTmXc6VLrasL8ufGNTE0PaRMFza7J8gueLqKIaPzxRriA2Zs6WoTcmh3HgZn6XqDEbY7Gjq6BG8xFouUgnWwT74AE3We3o_ReaT3ocU-0S5EupoqEac5ln4bbYaeLlr0wUK0zocB3pO3HfQJPxzPK_Lr5nq9_F7c_bz9sVzcFaDmLBe1Zo1tu0bqzrKqFVLYUjcgQTSylhwaqISsBLSsrECrGpnUyFQ9taTCbi6vyNcDdzs2A7YWfY7Qm210A8SdCeDM6xfvNuYhPBnOFGdVJSfC5yMhht8jpmwGlyz2PXgMYzJCK64YZ3M9RetD1MaQUsTuNIczs5dqJqnmlVRzlDp1P_676Kn51-IUKA-BPeMxjNFP__Yf4GfgNrrN</recordid><startdate>20230807</startdate><enddate>20230807</enddate><creator>Dorst, Daphne N.</creator><creator>Smeets, Esther M. M.</creator><creator>Klein, Christian</creator><creator>Frielink, Cathelijne</creator><creator>Geijs, Daan</creator><creator>Trajkovic-Arsic, Marija</creator><creator>Cheung, Phyllis F. Y.</creator><creator>Stommel, Martijn W. J.</creator><creator>Gotthardt, Martin</creator><creator>Siveke, Jens T.</creator><creator>Aarntzen, Erik H. J. G.</creator><creator>van Lith, Sanne A. M.</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8584-2546</orcidid></search><sort><creationdate>20230807</creationdate><title>Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma</title><author>Dorst, Daphne N. ; Smeets, Esther M. M. ; Klein, Christian ; Frielink, Cathelijne ; Geijs, Daan ; Trajkovic-Arsic, Marija ; Cheung, Phyllis F. Y. ; Stommel, Martijn W. J. ; Gotthardt, Martin ; Siveke, Jens T. ; Aarntzen, Erik H. J. G. ; van Lith, Sanne A. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a470t-980bcdfb38fc06d232c58ba3a2b3931aba62362ad056a849e038e0490bc34ef73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Antibodies - metabolism</topic><topic>Cancer-Associated Fibroblasts</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Caspase 3 - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Disease Models, Animal</topic><topic>Fibroblasts - metabolism</topic><topic>Mice</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Photochemotherapy</topic><topic>Serine Endopeptidases - metabolism</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dorst, Daphne N.</creatorcontrib><creatorcontrib>Smeets, Esther M. M.</creatorcontrib><creatorcontrib>Klein, Christian</creatorcontrib><creatorcontrib>Frielink, Cathelijne</creatorcontrib><creatorcontrib>Geijs, Daan</creatorcontrib><creatorcontrib>Trajkovic-Arsic, Marija</creatorcontrib><creatorcontrib>Cheung, Phyllis F. Y.</creatorcontrib><creatorcontrib>Stommel, Martijn W. J.</creatorcontrib><creatorcontrib>Gotthardt, Martin</creatorcontrib><creatorcontrib>Siveke, Jens T.</creatorcontrib><creatorcontrib>Aarntzen, Erik H. J. G.</creatorcontrib><creatorcontrib>van Lith, Sanne A. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dorst, Daphne N.</au><au>Smeets, Esther M. M.</au><au>Klein, Christian</au><au>Frielink, Cathelijne</au><au>Geijs, Daan</au><au>Trajkovic-Arsic, Marija</au><au>Cheung, Phyllis F. Y.</au><au>Stommel, Martijn W. J.</au><au>Gotthardt, Martin</au><au>Siveke, Jens T.</au><au>Aarntzen, Erik H. J. G.</au><au>van Lith, Sanne A. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2023-08-07</date><risdate>2023</risdate><volume>20</volume><issue>8</issue><spage>4319</spage><epage>4330</epage><pages>4319-4330</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5 year survival of 9%. One important limiting factor for treatment efficacy is the dense tumor-supporting stroma. The cancer-associated fibroblasts in this stroma deposit excessive amounts of extracellular matrix components and anti-inflammatory mediators, which hampers the efficacy of chemo- and immunotherapies. Systemic depletion of all activated fibroblasts is, however, not feasible nor desirable and therefore a local approach should be pursued. Here, we provide a proof-of-principle of using fibroblast activation protein (FAP)-targeted photodynamic therapy (tPDT) to treat PDAC. FAP-targeting antibody 28H1 and irrelevant control antibody DP47GS were conjugated to the photosensitizer IRDye700DX (700DX) and the chelator diethylenetriaminepentaacetic acid. In vitro binding and cytotoxicity were evaluated using the fibroblast cell-line NIH-3T3 stably transfected with FAP. Biodistribution of 111In-labeled antibody-700DX constructs was determined in mice carrying syngeneic tumors of the murine PDAC cell line PDAC299, and in a genetically engineered PDAC mouse model (CKP). Then, tPDT was performed by exposing the subcutaneous or the spontaneous PDAC tumors to 690 nm light. Induction of apoptosis after treatment was assessed using automated analyses of immunohistochemistry for cleaved caspase-3. 28H1-700DX effectively bound to 3T3-FAP cells and induced cytotoxicity upon exposure to 690 nm light, whereas no binding or cytotoxic effects were observed for DP47GS-700DX. Although both 28H1-700DX and DP47GS-700DX accumulated in subcutaneous PDAC299 tumors, autoradiography demonstrated that only 28H1-700DX reached the tumor core. On the contrary, control antibody DP47GS-700DX was only present at the tumor rim. In CKP mice, both antibodies accumulated in the tumor, but tumor-to-blood ratios of 28H1-700DX were higher than that of the control. Notably, in vivo FAP-tPDT caused upregulation of cleaved caspase-3 staining in both subcutaneous and in spontaneous tumors. In conclusion, we have shown that tPDT is a feasible approach for local depletion of FAP-expressing stromal cells in murine models for PDAC.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>37485886</pmid><doi>10.1021/acs.molpharmaceut.3c00453</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8584-2546</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1543-8384 |
ispartof | Molecular pharmaceutics, 2023-08, Vol.20 (8), p.4319-4330 |
issn | 1543-8384 1543-8392 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10410663 |
source | MEDLINE; ACS Publications |
subjects | Animals Antibodies - metabolism Cancer-Associated Fibroblasts Carcinoma, Pancreatic Ductal - pathology Caspase 3 - metabolism Cell Line, Tumor Disease Models, Animal Fibroblasts - metabolism Mice Pancreatic Neoplasms Pancreatic Neoplasms - metabolism Photochemotherapy Serine Endopeptidases - metabolism Tissue Distribution |
title | Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A31%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibroblast%20Activation%20Protein-Targeted%20Photodynamic%20Therapy%20of%20Cancer-Associated%20Fibroblasts%20in%20Murine%20Models%20for%20Pancreatic%20Ductal%20Adenocarcinoma&rft.jtitle=Molecular%20pharmaceutics&rft.au=Dorst,%20Daphne%20N.&rft.date=2023-08-07&rft.volume=20&rft.issue=8&rft.spage=4319&rft.epage=4330&rft.pages=4319-4330&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.3c00453&rft_dat=%3Cproquest_pubme%3E2841401078%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2841401078&rft_id=info:pmid/37485886&rfr_iscdi=true |